The FDA has approved Dupixent for the treatment of patients aged 12 years and older with CSU who remain symptomatic despite H1 antihistamine treatment.

The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) to treat adults and ...

The FDA has approved Dupixent as the first new targeted therapy in over ten years for chronic spontaneous urticaria in patients aged 12 and older who remain symptomatic despite antihistamine treatment ...